92 results
Page 2 of 5
6-K
EX-99
irszje39o8k fj5
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
424B5
84tg 1dx2kmtptojc
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
sgf9lzmrpm5snuyd65
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
wg2oxaese
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
8scf9c mnhlv
16 Mar 22
BioLineRx Reports Fourth Quarter 2021 Financial Results
7:11am
6-K
EX-99
u964aq
17 Dec 21
BioLineRx Provides Highlights from Oral Presentation
7:10am
6-K
EX-99
k07x v5l9e7ppfzu6wcr
15 Dec 21
BioLineRx Announces Formation of Immuno-Oncology
7:25am
6-K
EX-99
08mb060gpua51 xp0
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am
6-K
EX-99
dv2 uz651
18 Nov 21
BioLineRx Reports Third Quarter 2021 Financial Results
7:16am
6-K
EX-1
133oyzl3j
4 Nov 21
BioLineRx Announces an Oral Presentation and Three
10:15am
6-K
EX-99
kiwtkn
18 Aug 21
BioLineRx Reports Second Quarter 2021 Financial Results
7:01am
6-K
EX-99
ywpv69
26 May 21
BioLineRx Reports First Quarter 2021 Financial Results
7:54am
424B5
s40wb5tz
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
kvb9sul
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
eb9j2l8d2s2ifvy6zos
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
j3mofe19gaest2o
31 Dec 20
Prospectus supplement for primary offering
4:31pm
6-K
EX-99
z44o nw41
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am